LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Source: Newsfilter
Acquisition Agreement: LAVA Therapeutics has entered into a definitive agreement to be acquired by XOMA Royalty Corporation for $1.16 to $1.24 per share in cash, with the transaction expected to close in the fourth quarter of 2025, pending shareholder approval and customary conditions.
Program Discontinuation: The company announced the discontinuation of its LAVA-1266 program for acute myeloid leukemia and myelodysplastic syndrome, initiating the wind-down process while continuing development on partnered programs with Johnson & Johnson and Pfizer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
